Taste Properties of HIV Inhibitor | Clinical Trial

Key information

Conditions

HIV Infections Blood-Borne Infections Communicable Diseases Genital Diseases Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Urogenital Diseases Virus Diseases

Age range

25 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

GSK Investigational Site

Woburn, Massachusetts, 01801, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Men and women of non-childbearing potential professional sensory panelists
Aged between 25 and 80 years

Exclusion criteria

History of relevant drug or food allergies, cardiovascular or Central nervous system (CNS) disease, clinically significant pathology, history of mental illness
Positive HIV test

Treatment and study plan

BMS-955176

Drug

Other names: HIV Maturation Inhibitor

Primary outcomes

Taste properties of HIV Inhibitor will be measured using the Flavor Profile of the Flavor Leadership Criteria

Time frame: Up to 2 years

Sponsors and collaborators

Lead sponsor

ViiV Healthcare

Industry

Collaborators

Senopsys, LLC

Registry information

Official study title

An Open-Label Taste Assessment of BMS-955176 in Healthy Subjects

Important dates

Study start: 2016
Primary completion: 2016
Study completion: 2016
First posted: Nov 20, 2015
Registry last updated: Apr 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed